查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2110284

2026-2034年全球人工智慧（AI）市場規模、佔有率、趨勢和成長分析報告－藥物發現領域

Global Artificial Intelligence (AI) in Drug Discovery Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 155 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球人工智慧（AI）藥物研發市場預計將從2025年的27.7億美元成長至2034年的205.2億美元，2026年至2034年的複合年成長率（CAGR）為24.92%。隨著製藥公司尋求縮短研發時間和降低研發成本，藥物研發領域的人工智慧市場正經歷顯著成長。機器學習、深度學習和自然語言處理等人工智慧技術正被用於識別藥物標靶、預測分子行為以及最佳化臨床候選化合物的選擇。生技新創公司與大型製藥企業之間日益密切的合作也加速了人工智慧在早期研發階段的應用。

關鍵促進因素包括藥物研發成本不斷上漲、對提高成功率的需求以及取得大量生物醫學資料集。人工智慧平台能夠增強標靶檢驗、化合物篩檢和毒性預測，從而縮短藥物發現週期。運算能力的提升和雲端分析技術的進步進一步增強了擴充性。創業投資對人工智慧驅動的生物技術公司的投入正在推動創新並拓展競爭格局。

未來，人工智慧可望在藥物研發的各個階段發揮不可或缺的作用，包括臨床試驗設計和真實世界數據分析。與基因組學、蛋白質組學和患者數據的整合將使治療更加精準。人工智慧產生的洞見獲得監管部門的批准以及數據的透明度預計將對長期成長產生影響。隨著演算法的成熟和檢驗的改進，人工智慧主導的研發流程有望顯著重塑製藥業的創新格局。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：本節詳細評估影響市場成長的主要促進因素、限制因素、機會和挑戰。內容涵蓋技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球人工智慧（AI）在藥物研發領域的市場：按應用分類

  • 市場分析、洞察與預測
  • 藥物最佳化與仿單標示外用藥
  • 臨床前試驗
  • 其他

第5章：全球人工智慧（AI）在藥物研發領域的市場：依治療領域分類

  • 市場分析、洞察與預測
  • 腫瘤學
  • 神經退化性疾病
  • 心血管疾病
  • 代謝性疾病
  • 感染疾病
  • 其他

第6章：全球人工智慧（AI）在藥物研發領域的市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • IBM Corporation
    • Exscientia Plc
    • Insilico Medicine Inc
    • Aitia（formerly GNS Healthcare）
    • Google DeepMind
    • BenevolentAI
    • BioSymetrics Inc
    • Berg Health（acquired By BPGbio）
    • Atomwise Inc
    • Insitro
    • Cyclica（now Part Of Recursion Pharmaceuticals）
簡介目錄
Product Code: VMR11218721

The global artificial intelligence (AI) in drug discovery market size is expected to reach USD 20.52 Billion in 2034 from USD 2.77 Billion in 2025, growing at a CAGR of 24.92 during 2026-2034.The AI in drug discovery market has witnessed significant growth as pharmaceutical companies seek to reduce R&D timelines and costs. AI technologies-such as machine learning, deep learning, and natural language processing-are used to identify drug targets, predict molecular behavior, and optimize clinical candidate selection. Growing collaboration between biotech startups and large pharmaceutical firms has accelerated AI adoption in early-stage research.

Primary drivers include rising drug development costs, the need for higher success rates, and access to vast biomedical datasets. AI platforms enhance target validation, compound screening, and toxicity prediction, shortening discovery cycles. Advances in computational power and cloud-based analytics further support scalability. Venture capital investment in AI-driven biotech firms has fueled innovation and expanded the competitive landscape.

Looking ahead, AI is expected to become integral across the drug development continuum, including clinical trial design and real-world evidence analysis. Integration with genomics, proteomics, and patient data will enable more precise therapies. Regulatory acceptance of AI-generated insights and data transparency will influence long-term growth. As algorithms mature and validation improves, AI-driven pipelines may significantly reshape pharmaceutical innovation.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Application

  • Drug Optimization and Repurposing
  • Preclinical Testing
  • Others

By Therapeutic Area

  • Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Disease
  • Metabolic Diseases
  • Infectious Disease
  • Others

COMPANIES PROFILED

  • IBM Corporation, Exscientia plc, Insilico Medicine Inc., Aitia (formerly GNS Healthcare), Google DeepMind, BenevolentAI, BioSymetrics Inc., Berg Health (acquired by BPGbio), Atomwise Inc., insitro, Cyclica (now part of Recursion Pharmaceuticals)

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Application
  • 4.2. Drug Optimization and Repurposing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Preclinical Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Neurodegenerative Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Application
    • 6.2.2 By Therapeutic Area
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Application
    • 6.3.2 By Therapeutic Area
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Application
    • 6.4.2 By Therapeutic Area
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Application
    • 6.5.2 By Therapeutic Area
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Application
    • 6.6.2 By Therapeutic Area
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 IBM Corporation
    • 8.2.2 Exscientia Plc
    • 8.2.3 Insilico Medicine Inc
    • 8.2.4 Aitia (formerly GNS Healthcare)
    • 8.2.5 Google DeepMind
    • 8.2.6 BenevolentAI
    • 8.2.7 BioSymetrics Inc
    • 8.2.8 Berg Health (acquired By BPGbio)
    • 8.2.9 Atomwise Inc
    • 8.2.10 Insitro
    • 8.2.11 Cyclica (now Part Of Recursion Pharmaceuticals)